MEKiAUTO: A multicenter phase 1 study of combination therapy with the MEK inhibitor, cobimetinib, immune checkpoint blockade, atezolizumab, and the autophagy inhibitor hydroxychloroquine (HCQ) in KRAS-mutated advanced malignancies

Manji, G. A., Labadie, B. W., Lee, S. M., Pellicciotta, I., Ge, L., Sta Ana, S., Sender, N., Ross, I., Wong, W., & Raufi, A. G. (2023). MEKiAUTO: A multicenter phase 1 study of combination therapy with the MEK inhibitor, cobimetinib, immune checkpoint blockade, atezolizumab, and the autophagy inhibitor hydroxychloroquine (HCQ) in KRAS-mutated advanced malignancies. JCO Global Oncology, 9(Supplement_1), 45–45. https://doi.org/10.1200/go.2023.9.supplement_1.45
Authors:
Gulam A. Manji
Brian Labadie
Shing M. Lee
Ilenia Pellicciotta
Liner Ge
Sarah Sta Ana
Naomi Sender
I.N. Ross
W. Douglas Wong
Alexander G. Raufi
Affiliated Authors:
Gulam A. Manji
Brian Labadie
Liner Ge
Sarah Sta Ana
Naomi Sender
I.N. Ross
Columbia Affiliation:
Subjects:
Pancreatic Cancer Research and Treatment (OpenAlex Topic)
Role of Autophagy in Disease and Health (OpenAlex Topic)
Genomic Landscape of Cancer and Mutational Signatures (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.1200/go.2023.9.supplement_1.45
DOI:
10.1200/go.2023.9.supplement_1.45
Journal:
JCO Global Oncology
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record

Record Created: